{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:51:47Z","timestamp":1791899507725,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013143","name":"National Natural Science Foundation of China-Shandong Joint Fund for Marine Science Research Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013143","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.canlet.2025.217504","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:05:50Z","timestamp":1738022750000},"page":"217504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Thyroxine alleviates interstitial lung disease induced by combined radiotherapy and immunotherapy"],"prefix":"10.1016","volume":"615","author":[{"given":"You","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6762-7997","authenticated-orcid":false,"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217504_bib1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.canlet.2025.217504_bib2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/resp.13915","article-title":"Pulmonary toxicity of systemic lung cancer therapy","volume":"25","author":"Long","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.canlet.2025.217504_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett."},{"issue":"2023","key":"10.1016\/j.canlet.2025.217504_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canlet.2025.217504_bib5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"2nd, management of stage III non-small-cell lung cancer: ASCO guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib6","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.23.00627","article-title":"Selective personalized RadioImmunotherapy for locally advanced non-small-cell lung cancer trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/jamaoncol.2023.3309","article-title":"Durvalumab plus concurrent radiotherapy for treatment of locally advanced non-small cell lung cancer: the DOLPHIN phase 2 nonrandomized controlled trial","volume":"9","author":"Tachihara","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.arbres.2024.05.025","article-title":"Sex-specific difference for small cell lung cancer from immunotherapy advancement","author":"Mo","year":"2024","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.canlet.2025.217504_bib9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217001","article-title":"Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: a retrospective cohort study","volume":"596","author":"Fletcher","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217504_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216998","article-title":"Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: a nationwide retrospective cohort study","volume":"596","author":"Kim","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217504_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00038-2020","article-title":"Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis","volume":"55","author":"Moey","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.canlet.2025.217504_bib14","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","article-title":"Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study","volume":"15","author":"Suzuki","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib16","first-page":"370","article-title":"Highlights from the 2023 American society of clinical Oncology annual meeting: lung cancer","volume":"21","author":"Kim","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.canlet.2025.217504_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.canlet.2025.217504_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.canlet.2025.217504_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2307\/2686094","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"O'Neill Rt","year":"1999","journal-title":"Am Stat"},{"key":"10.1016\/j.canlet.2025.217504_bib21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.canlet.2025.217504_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2025.217504_bib23","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/ije\/dyx102","article-title":"Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption","volume":"46","author":"Hartwig","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.canlet.2025.217504_bib24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet. Epidemiol."},{"key":"10.1016\/j.canlet.2025.217504_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.canlet.2025.217504_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061561","article-title":"Radiation-induced lung fibrosis: preclinical animal models and therapeutic strategies","volume":"12","author":"Jin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2025.217504_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2307\/3577925","article-title":"The genetic basis of strain-dependent differences in the early phase of radiation injury in mouse lung","volume":"126","author":"Franko","year":"1991","journal-title":"Radiat. Res."},{"key":"10.1016\/j.canlet.2025.217504_bib28","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41467-023-38134-z","article-title":"An interactive murine single-cell atlas of the lung responses to radiation injury","volume":"14","author":"Curras-Alonso","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217504_bib29","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cllc.2019.06.009","article-title":"Prognostic variables associated with improved outcomes in patients with stage III NSCLC treated with chemoradiation followed by consolidation pembrolizumab: a subset analysis of a phase II study from the hoosier cancer research network lun 14-179","volume":"21","author":"Anouti","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.canlet.2025.217504_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2022.10.006","article-title":"Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: the phase II DETERRED trial","volume":"174","author":"Liu","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2025.217504_bib32","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2025.217504_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00165-2019","article-title":"Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study","volume":"6","author":"Pozzessere","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.canlet.2025.217504_bib35","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.annonc.2020.09.016","article-title":"Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors","volume":"31","author":"Shaverdian","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","article-title":"Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"146","author":"Jung","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2025.217504_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12916-022-02713-6","article-title":"Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation","volume":"21","author":"Guo","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2025.217504_bib38","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.21037\/tlcr-20-192","article-title":"Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis","volume":"9","author":"Liang","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.canlet.2025.217504_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113373","article-title":"A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: the SPIRAL-RT study","volume":"195","author":"Yamada","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.217504_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26650-9","article-title":"Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer","volume":"12","author":"Polverino","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2025.217504_bib41","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1161\/HYPERTENSIONAHA.123.22393","article-title":"PD-1\/PD-L1 provides protective role in hypoxia-induced pulmonary vascular remodeling","volume":"81","author":"Wang","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.canlet.2025.217504_bib42","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ijrobp.2020.11.038","article-title":"Polymorphonuclear-MDSCs facilitate tumor regrowth after radiation by suppressing CD8(+) T cells","volume":"109","author":"Zhang Md","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2025.217504_bib43","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ijrobp.2023.02.005","article-title":"Cellular atlas of senescent lineages in radiation- or immunotherapy-induced lung injury by single-cell RNA-sequencing analysis","volume":"116","author":"Wu","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2025.217504_bib44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.canlet.2015.04.013","article-title":"The differential role of human macrophage in triggering secondary bystander effects after either gamma-ray or carbon beam irradiation","volume":"363","author":"Dong","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217504_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216239","article-title":"Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: a promising strategy of combining with radiotherapy","volume":"565","author":"Kang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217504_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111263","article-title":"Cytokine, chemokine alterations and immune cell infiltration in Radiation-induced lung injury: implications for prevention and management","volume":"126","author":"Guo","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.canlet.2025.217504_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2021.01.001","article-title":"Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer","volume":"157","author":"Cousin","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib48","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bcp.14433","article-title":"Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy","volume":"86","author":"Mangan","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.canlet.2025.217504_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216268","article-title":"Particle radiotherapy in the era of radioimmunotherapy","volume":"567","author":"Zhou","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217504_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cells11101593","article-title":"Cell-surface programmed death ligand-1 expression identifies a sub-population of distal epithelial cells enriched in idiopathic pulmonary fibrosis","volume":"11","author":"Ahmadvand","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2025.217504_bib51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4158\/EP09021.CRR","article-title":"Reversibility of fibrotic appearance of lungs with thyroxine replacement therapy in patients with severe hypothyroidism","volume":"15","author":"George","year":"2009","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.canlet.2025.217504_bib52","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.canlet.2025.217504_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-022-02697-3","article-title":"Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response","volume":"21","author":"Chen","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.canlet.2025.217504_bib54","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2025.217504_bib55","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217504_bib56","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"key":"10.1016\/j.canlet.2025.217504_bib57","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1586\/17512433.2013.811206","article-title":"Perils and pitfalls of long-term effects of proton pump inhibitors","volume":"6","author":"Wilhelm","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.canlet.2025.217504_bib58","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s12013-014-0030-5","article-title":"Effects of proton pump inhibitors on lung cancer precise radiotherapy-induced radiation pneumonitis","volume":"70","author":"Su","year":"2014","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.canlet.2025.217504_bib59","article-title":"Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis","volume":"78","author":"Dar","year":"2022","journal-title":"Ann Med Surg (Lond)"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:22:34Z","timestamp":1741270954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":59,"alternative-id":["S0304383525000680"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217504","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroxine alleviates interstitial lung disease induced by combined radiotherapy and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217504"}}